Eupraxia Pharmaceuticals Net Income

Eupraxia Pharmaceuticals (EPRX) currently reports a net income of $-59M as of June 2026. That compares with $-29M in the prior-year period — down 104.0% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Eupraxia Pharmaceuticals's net income history and peer comparisons.

Eupraxia Pharmaceuticals's net income decreased from $-29M to $-59M — a 104.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eupraxia Pharmaceuticals's net income of $-59M is lower than the Healthcare sector average of $16B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eupraxia Pharmaceuticals reported $-59M in net income as of June 2026. That compares with $-29M in the prior-year period — down 104.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-59M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Eupraxia Pharmaceuticals, and consider following EPRX for alerts when major investors trade the stock.